Vitamin D and Canker Sores — What the Evidence Shows

TL;DR

Recurrent aphthous stomatitis (RAS) patients consistently show lower serum 25-hydroxyvitamin D [25(OH)D] levels than controls across multiple independent studies. Vitamin D has well-characterized immune-regulatory roles that are directly relevant to the pathology driving canker sores — particularly its suppression of the inflammatory T-cell response and its upregulation of antimicrobial peptides at mucosal surfaces. Two small intervention studies suggest that correcting deficiency reduces canker sore frequency. The evidence base is not as strong as for Vitamin B12 (no large placebo-controlled RCT in non-deficient patients), but deficiency is extraordinarily common in the general population and the mechanistic logic is sound. If you have frequent canker sores, getting your Vitamin D status checked and correcting deficiency if present is a low-risk, high-potential intervention.

Why Vitamin D Is Relevant to Canker Sores

The pathology of canker sores involves an aberrant immune attack on the oral mucosa. CD8+ cytotoxic T-lymphocytes target epithelial cells, driven by inflammatory cytokines — TNF-α, IL-2, IFN-γ. The immune dysregulation is the disease.

Vitamin D (as its active form, 1,25-dihydroxyvitamin D3 / calcitriol) is a potent immune modulator with several direct points of contact with this process:

Regulation of T-Cell Activity

The Vitamin D receptor (VDR) is expressed on virtually all immune cells, including T-lymphocytes. When occupied by calcitriol, VDR:

• Suppresses the differentiation of Th1 cells (which produce IFN-γ and IL-2 — both drivers of aphthous mucosal destruction)
• Promotes regulatory T-cell (Treg) activity — Tregs dampen aberrant autoimmune-type responses
• Inhibits production of the pro-inflammatory cytokines TNF-α and IL-12

These are precisely the inflammatory mediators implicated in RAS pathogenesis. Vitamin D deficiency removes a brake on the type of T-cell response that destroys oral epithelium.

Mucosal Antimicrobial Defense

Vitamin D upregulates the production of cathelicidin (LL-37) and beta-defensins — antimicrobial peptides that are part of innate mucosal immunity. These peptides are produced by epithelial cells and play a dual role: direct antimicrobial activity against oral pathogens, and modulation of the local inflammatory response. Lower Vitamin D → lower cathelicidin → reduced mucosal barrier function.

Epithelial Repair

VDR signaling promotes keratinocyte proliferation and differentiation. This is relevant to re-epithelialization — the healing process that closes the ulcer. Deficiency may slow the healing phase even if it isn't the primary trigger.

The Observational Evidence

Multiple studies have compared serum 25(OH)D levels between RAS patients and controls:

Ölmez et al. (2007) — Significantly lower serum 25(OH)D in Turkish RAS patients versus controls. The difference remained significant after controlling for sun exposure and dietary intake.

Compilato et al. (2010 — PMID: 20403088) — Found lower serum 25-OH-D3 in Italian patients with recurrent oral ulceration versus controls. Also found lower serum zinc and B vitamins, consistent with a pattern of broad micronutrient depletion in RAS patients.

Nolan et al. (2009 — PMID: 19178623) — In a prospective analysis of hematinic and nutritional deficiencies in 500+ RAS patients, documented elevated rates of micronutrient deficiency consistent with impaired mucosal immunity.

Esen et al. (2020 — PMID: 31849023) — Turkish case-control study finding significantly lower serum 25(OH)D3 in RAS patients (mean 14.4 ng/mL vs. 22.7 ng/mL in controls). The RAS group showed levels well below the standard 20 ng/mL threshold considered sufficient.

Gümüş et al. (2019) — Identified inverse correlation between Vitamin D levels and RAS severity — patients with major aphthous ulcers had lower D levels than those with minor aphthous ulcers.

The pattern across these studies is consistent: RAS patients have lower Vitamin D than controls, and the magnitude of deficiency tracks with disease severity.

Caveat: Correlation vs. Causation

This is observational data. Two alternative interpretations exist:

1. Low Vitamin D causes or worsens RAS through immune dysregulation — the preferred hypothesis given the mechanistic logic
2. Confounding — whatever lifestyle or genetic factors predispose to RAS also happen to produce lower Vitamin D (less outdoor activity due to illness, inflammatory conditions that consume 25(OH)D, shared predisposing conditions)

Intervention studies are needed to distinguish these. Small intervention studies exist and show promising results, but a large placebo-controlled RCT in the style of the Volkov B12 trial has not been conducted.

Intervention Studies

Mansueto et al. (2021 — PMID: 34234958) — A small Italian intervention study supplementing Vitamin D in RAS patients with documented deficiency. After 4 months of supplementation (correcting to sufficiency), 56% of patients reported significant reduction in outbreak frequency and severity. Uncontrolled design limits conclusions, but direction is consistent with the mechanistic hypothesis.

Arikan et al. (2020) — Small Turkish RCT (32 patients) comparing Vitamin D supplementation to placebo in RAS patients. The supplemented group showed significant reduction in number of ulcers and pain severity over 3 months. This is the strongest direct intervention evidence currently available, though the sample size is small.

The direct evidence base is promising but thin relative to B12. The mechanistic logic and the consistent observational pattern make this a rational intervention, particularly in deficient patients.

Deficiency Is Extremely Common

This context matters. Vitamin D deficiency is not a niche problem:

• The CDC estimates that approximately 41% of U.S. adults have serum 25(OH)D below 20 ng/mL (the standard sufficiency threshold)
• Deficiency is higher in people with dark skin (reduced cutaneous synthesis), people in northern latitudes, people who work indoors, and older adults
• Low dietary fat intake impairs Vitamin D absorption (it's fat-soluble)
• Obesity sequesters Vitamin D in adipose tissue, reducing circulating levels

Given that roughly 40% of the population is already deficient, the probability that a given RAS patient is deficient is meaningfully higher than average — and correction of an extremely common deficiency is a low-threshold intervention.

Getting Tested

Standard clinical test: serum 25-hydroxyvitamin D [25(OH)D], also written as 25-OH-D or Vitamin D3 level.

Interpretation:

• <12 ng/mL — Severe deficiency
• 12–20 ng/mL — Deficiency
• 20–30 ng/mL — Insufficient (functional impairment possible)
• 30–50 ng/mL — Sufficient
• >50 ng/mL — Optimal by many functional medicine standards (not universally agreed)
• >100 ng/mL — Toxicity risk

Most RAS patients in the observational studies cited above had levels in the 12–20 ng/mL range — clinical deficiency territory.

Testing is inexpensive and often covered by routine blood work. If you have a doctor visit for any reason, adding a 25(OH)D to the order costs little.

How to Supplement

Form: Vitamin D3 (cholecalciferol) — the animal-derived form, identical to what the skin synthesizes from UVB exposure. More potent at raising serum levels than D2 (ergocalciferol).

Dose for deficiency correction:

• Mild insufficiency (20–30 ng/mL): 2,000 IU/day
• Moderate deficiency (12–20 ng/mL): 4,000–5,000 IU/day
• Severe deficiency (<12 ng/mL): 5,000–10,000 IU/day, ideally with medical supervision
• Maintenance once sufficient: 1,000–2,000 IU/day

Fat-soluble absorption: Vitamin D is fat-soluble — take it with your largest meal of the day, or with a source of dietary fat (olive oil, nuts, avocado). Oil-based softgel formulations (like coconut oil-based D3) improve absorption compared to dry powder capsules.

Vitamin K2 co-supplementation: At higher D3 doses (>2,000 IU), pairing with Vitamin K2 (MK-7 form, 100–200mcg) is commonly recommended. Vitamin D increases calcium absorption; K2 directs calcium to bones rather than soft tissues, including arterial walls. This is a reasonable precaution at corrective doses.

Retest: Retest 25(OH)D after 3 months of supplementation to confirm levels have corrected. Adjust dose based on results.

Vitamin D in Context with Other RAS Supplements

Vitamin D does not operate in isolation. The immune regulatory functions relevant to RAS overlap with other micronutrients:

These are not competing interventions — they work via different pathways and can be taken simultaneously. If you have documented deficiency in multiple nutrients, correcting all of them is more likely to be useful than correcting one while ignoring the others.

For the full supplement hierarchy, see The Best Supplements for Canker Sore Prevention.